Columbia University College of Physicians and Surgeons

Slides:



Advertisements
Similar presentations
Aggressive Management of Chronic Deep Venous Thrombosis: Technical and Clinical Outcomes Mark J. Garcia M.D. FSIR C Grilli, M McGarry, M Ali, D Agriantonus,
Advertisements

VTE in abdominal-pelvic surgery patients
+ Deep Vein Thrombosis Common, Preventable, and potentially Fatal.
Results: 1.Progression of thrombus length and volume (40% vs. 28%; P
Long-Term Outcome After Additional Catheter-Directed Thrombolysis versus Standard Treatment for Acute Iliofemoral Deep Vein Thrombosis (The CaVenT Study):
Chapter Eleven Venous Disease Coalition Chronic Venous Insufficiency VTE Toolkit.
Complications Of Vena Cava Filters Amr Fares MD,FRCS Assistant prof. of surgery,Weill cornell college of medicine Vascular surgery consultant Doha –Qatar.
DPT 732 SPRING 2009 S. SCHERER Deep Vein Thrombosis.
Venous Thromboembolism Safety Tool Kit Brenda K. Zierler, PhD, RN, RVT University of Washington Medication Safety: Tools for Diverse Settings September.
Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?
IVC filters what you need to know Sam Chakraverty Consultant Radiologist Ninewells Hospital Dundee, Scotland.
Thrombus Obliteration by Rapid Percutaneous Endovenous Intervention in Deep Venous Occlusion “TORPEDO” trial : Mid –Term results Mohsen Sharifi,MD,FACC,
Conclusions Results Methods Background Venous thrombo-embolism in patients undergoing neo- adjuvant chemotherapy and surgery for oesophago-gastric cancer.
Outpatient DVT assessment & treatment Daniel Gilada.
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
Clinical case Case Presentation: IVC Retrievable and Permanent Filters
Novel Trial Design Focus - Left Main and “All Comers” DES Studies: All-Comers Studies. Interventional View Jeffrey J. Popma, MD Director, Innovations in.
Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Vivek Y. Reddy.
IVC Filter Placement Which and How
CRT 2012 Venous Disease.
Treatment of VTE Guidelines
Iliac and Aortiliac Occlusions: Stent Grafts or Bare Metal Stents…
Management of Patients on Chronic Oral Anticoagulant Therapy
Venous Thromboembolism Prophylaxis (VTE)
Deep Venous Thrombosis Anthony J. Comerota, MD, FACS, FACC
Impact of Radial Access on Bleeding
MCV Campus Ginger Edwards.
The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,
CRT 2012 Venous Disease.
Innovative DVT Therapy in 2016: Merely the End of the Beginning
Claret Cerebral Protection Device: Implications of the Sentinel Study
Insights Using Data from California Richard H. White MD
Aorta Infrarenal Stenosis: BE, SE or Covered Stents? CRT 2012
For the HORIZONS-AMI Investigators
APEX Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for days (n = 3,759) versus subcutaneous.
Japan-USA Synergies: Academic View
TAVI „Catch me if you can!“
Jaideep Patel, Stephanie Detterline, M.D., Robert Ferguson, M.D.
The TREAT Study: Can Devices Lower Bleeding Rates?
Dr.H.Chandrashekar, Dr.A.Chaudhuri, Dr. A. Douglas, Dr. D. Lowdon
L. Nelson Hopkins, MD DISCLOSURES Consulting Fees
The Tryton Bifurcation Trial:
SYNTAX at 2 Years: This Interventionalist’s Perspective
DES Should be Used as the Default Stent in ACS!
Copyright © 2012 American Medical Association. All rights reserved.
Ortho Warfarin Dosing Protocol
Instent Restenosis and Occlusion: Time for Surgical Revision?
Is There a Role for Aspiration in STEMI?
Carotid Artery Stenting for Stroke Prevention
S.G. Worthley, MB, BS, PhD., S. Redwood, MD, PhD.,
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients
Optional IVC Filters: Indications for Placement and Retrieval
The Guidelines Should Be Change!
CRT 2012 Primer for Endovascular Interventions
Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S
New Strategies to Prevent CV Events After Hospital Discharge
Dabigatran in myocardial injury after noncardiac surgery
Owen N. Johnson, MD, David L
How and why this study may change my practice ?
Carotid Artery Stenting for Stroke Prevention
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
Impact of consensus statements and reimbursement on vena cava filter utilization  Sapan S. Desai, MD, PhD, MBA, Abdallah Naddaf, MD, James Pan, MD, Douglas.
Dabigatran in myocardial injury after noncardiac surgery
Post-thrombotic Syndrome.
Managing Pulmonary Embolism Posthospital Discharge
How I treat cancer-associated venous thromboembolism
Volume 135, Issue 2, Pages (February 2009)
Dabigatran in myocardial injury after noncardiac surgery
Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.
Presentation transcript:

Columbia University College of Physicians and Surgeons Classes of Filters and Complications John H. Rundback, MD, FAHA, FSVMB, FSIR The Interventional Institute at Holy Name Hospital Columbia University College of Physicians and Surgeons

John H. Rundback, MD DISCLOSURES Consulting Fees Honoraria ev3, Inc., Medtronic CardioVascular, Inc., Boston Scientific Corporation Honoraria Medtronic CardioVascular, Inc., Boston Scientific Corporation Grants/Contracted Research DSMC for VIVA (Abbott Trial), ev3, Inc., Abbott Vascular, C.R. Bard, Inc., Atrium Medical Corporation, W. L. Gore & Associates, Inc., Cordis, a Johnson & Johnson company, Terumo Medical Corporation

Classes of Filters Permanent Temporary Filter attached to tether Must be removed Optional – Retrievable Self-affixing to IVC wall Permanence is optional Optional – Convertible Self –affixing to IVC wall Device is permanent, but filtration is optional

NON-PERMANENT

Option Filter (Rex Medical) SafeFlo Filter (Rafael Medical) Crux Filter (Crux Biomedical) ALN Filter (ALN Implants)

IVC Filter Complications Death Caval Thrombosis Breakthrough PE Deep Venous Thrombosis Post-phlebitic syndrome Migration Embolization Caval Penetration Caval Injury with retrieval

SIR QI Guidelines (JVIR 2003)

Cardiac Migration Essentially no difference across permanent filter types Chest. 2009 Sep;136:877-87

Fracture and Cardiac Migration JVIR 2008 July

Caval Thrombosis and DVT

Decousus Study 400 patients with proximal DVT Randomized to anticoagulation vs. filter and anticoagulation Outcome measures: death, recurrent VTE, major bleeding Analysis at day 12 and 2 years NEJM February 2008

2 year f/u DVT: 20% with filter, 12% without (p<0.05) Recurrent PE, death: no difference

PREPIC 8-Year Update Recurrent DVT Filter: 57 (34.1%) 50% filter + DVT had filter thrombosis No filter: 41 (27.3%) Symptomatic PE Filter: 9 (6.2%), 2 fatal No filter: 24 (15.1%) 5 fatal Post–thrombotic syndrome: 56% in both groups Ulcers 5 filter, 15 non-filter No survival benefit with filter P=0.042 P=0.008 Circulation 2005;112:416

11 articles, 1552 patients, 4.5 yr mean f/u JVIR July 2008 11 articles, 1552 patients, 4.5 yr mean f/u One study reported no difference in PTS according to whether anticoagulation was initiated in addition to filter placement. No study reported rates of PTS according to use of elastic compression stockings after filter placement. Pooled Weighted Frequency of PTS Indication # pts Edema Trophic ∆‘s or ulcer Mean f/u 1o Prevention 302 20.2% 8.3% / 2% 2.1 y 2o Prevention 1103 51.2% 13.5% / 3.8% 5.6 y

JVIR Mar 2008 Recovery and Tulip Filters 15.5% of retrievable filters underwent attempted removal  70% successfully retrieved

Failed Retrieval

Conclusions There is an increasing trend towards the placement of optional IVC filters although most are not removed. No substantial differences in major complications exist across filter classes or types. Major risk is recurrent VTE which occurs in approximately 20% of cases.